Drug Trial Radar · NCT07777211
A Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
52
Planned (sponsor's estimate)
Start
Aug 14, 2025
Primary completion
Mar 31, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Beijing Gene Key Life Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I/IIa, multicenter study designed to evaluate the safety, tolerability, and efficacy of GKL-006 injection in patients with ductal adenocarcinoma of pancreas.
Conditions
- Advanced Pancreatic Cancer
- Ductal Adenocarcinoma of Pancreas
Interventions
GKL-006 injectionBiological
GKL-006 injection will be administered at the protocol-defined dose every 2 weeks. Participants in Phase I will receive the assigned low or high dose, and recommended dose in Phase II.
Nab-paclitaxel and GemcitabineDrug
Nab-paclitaxel and Gemcitabine are given intravenously as a combination chemotherapy regimen according to the study protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: Incidence of Dose-Limiting ToxicitiesTime frame: From the first dose until 42 days
- Phase I: Incidence and Severity of Adverse Events and Serious Adverse EventsTime frame: Up to 18 months
- Phase II: Progression-Free Survival (PFS) Assessed by Independent Review Committee (IRC) per RECIST 1.1Time frame: Up to 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
No. 1 Shuaifuyuan, Wangfujing, Dongcheng District
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.